Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ligand Pharmaceuticals (LGND) Cash from Financing Activities: 2010-2025

Historic Cash from Financing Activities for Ligand Pharmaceuticals (LGND) over the last 15 years, with Sep 2025 value amounting to $409.6 million.

  • Ligand Pharmaceuticals' Cash from Financing Activities rose 643.73% to $409.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $440.3 million, marking a year-over-year increase of 436.48%. This contributed to the annual value of $97.1 million for FY2024, which is 262.04% up from last year.
  • Ligand Pharmaceuticals' Cash from Financing Activities amounted to $409.6 million in Q3 2025, which was up 2,631.88% from $15.0 million recorded in Q2 2025.
  • Ligand Pharmaceuticals' 5-year Cash from Financing Activities high stood at $409.6 million for Q3 2025, and its period low was -$170.4 million during Q1 2022.
  • Moreover, its 3-year median value for Cash from Financing Activities was $9.5 million (2024), whereas its average is $41.6 million.
  • Per our database at Business Quant, Ligand Pharmaceuticals' Cash from Financing Activities crashed by 998,000.00% in 2021 and then spiked by 1,671.87% in 2024.
  • Ligand Pharmaceuticals' Cash from Financing Activities (Quarterly) stood at $4.2 million in 2021, then crashed by 227.23% to -$5.3 million in 2022, then surged by 200.32% to $5.3 million in 2023, then soared by 283.59% to $20.4 million in 2024, then skyrocketed by 643.73% to $409.6 million in 2025.
  • Its Cash from Financing Activities stands at $409.6 million for Q3 2025, versus $15.0 million for Q2 2025 and -$4.7 million for Q1 2025.